APA (7th ed.) Citation

T, F., RM, S., DJ, D., I, G., E, E., C, L., . . . FJ, G. (2010). Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(28), 4339. https://doi.org/10.1200/JCO.2010.28.9678

Chicago Style (17th ed.) Citation

T, Fischer, et al. "Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-like Tyrosine Kinase 3 Receptor (FLT3) and Multi-targeted Kinase Inhibitor, in Patients with Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome with Either Wild-type or Mutated FLT3." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 28, no. 28 (2010): 4339. https://doi.org/10.1200/JCO.2010.28.9678.

MLA (9th ed.) Citation

T, Fischer, et al. "Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-like Tyrosine Kinase 3 Receptor (FLT3) and Multi-targeted Kinase Inhibitor, in Patients with Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome with Either Wild-type or Mutated FLT3." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 28, no. 28, 2010, p. 4339, https://doi.org/10.1200/JCO.2010.28.9678.